Skip to main content

Table 3 Disease progression incidence rate, PFS time and OS time

From: Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study

 

Disease progression incidence rate

Kaplan-Meir estimated progression-free survival

Kaplan-Meier-estimated overall survival

N

Patients with disease progression assessment

Total follow up time in first line treatment (years)

Incidence Rate (95% CI)

(person-years)

N

12-month PFS

Median PFS (95% CI) (months)

Hazard Ratio

(95% CI); p-value, univariate analysis

N

12-month survival rate

Median OS(95% CI) (months)

Hazard Ratio (95% CI); p-value; univariate analysis

Overall patient population

 

357

147

256.7

0.57

(0.48–0.67)

373

76.0

(71.2–80.1)

22.4

(20.4–24.7)

n/a

379

88.8

(85.1–91.6)

45.0

(40.9–55.0)

n/a

Patient subpopulations per MBC diagnosis state

 

First diagnosed at an earlier stage

208

110

129.1

0.85

(0.69–1.01)

221

68.1

(59.7–75.1)

20.4

(17.8–22.8)

1.42

(1.12–1.81);

p = 0.004

227

87.9

(82.9–91.6)

41.0

(36.9–48.4)

1.37

(0.97–1.93); p = 0.073

de novo Diagnosis

149

37

127.6

0.29

(0.20–0.38)

152

82.7

(75.5–88.0)

26.8

(21.8–30.3)

152

90.1

(84.1–93.9)

not reached

Patient subpopulations per HR/HER2 status

 

HR+/HER2

182

76

161.0

0.47

(0.37–0.58)

187

79.2

(72.5–84.5)

24.6

(21.3–27.9)

HR+/HER2+ vs. HR+/HER2

1.48 (1.05–2.09); p = 0.027

HR/HER2+ vs. HR+/HER2

1.21 (0.82–1.77); p = 0.337

HR/HER vs. HR+/HER2

1.52 (1.06–2.16); p = 0.023

189

94.1

(89.6–96.7)

48.4

(36.3–61.0)

HR+/HER2+ vs. HR+/HER21.00 (0.60–1.68); p = 0.992

HR/HER2+ vs. HR+/HER21.71 (1.05–2.78); p = 0.032

HR/HER vs. HR+/HER21.79 (1.12–2.87); p = 0.015

HR+/HER2+

51

21

29.7

0.71

(0.40–1.01)

55

67.5

(53.0–78.4)

19.7

(12.9–25.9)

56

89.3

(77.7–95.0)

45.6

(21.5–65.3)

HR/HER2+

43

22

25.5

0.86

(0.50–1.22)

42

85.6

(70.8–93.3)

23.0

(16.6–29.7)

43

92.9

(79.5–97.6)

34.0

(25.5–45.6)

HR/HER2

45

16

19.9

0.80

(0.41–1.20)

47

62.2

(46.3–74.6)

18.3

(10.0–24.7)

49

72.9

(58.1–83.3)

40.4

(18.4–55.0)

  1. Disease progression incidence rate, and the Kaplan-Meier estimated PFS time and OS time along with the 95% confidence intervals and hazard ratios of univariate analyses (p-values in bold indicated statistical significance) are displayed in the overall population and subpopulations per state of MBC diagnosis and HR/HER2 status. CI, confidence interval; N, number of patients analyzed for each outcome; n/a, not applicable